Instrument Inactif

Autres langues CROSSJECT Euronext Paris

Actions

FR0011716265

Equipement, fournitures et distribution médicale

Cours en clôture Euronext Paris Autres places de cotation
- ^EUR	-

29/05	Agenda des dividendes et des AG France : les coupons Kering et Cagemini arrivent
26/05	CROSSJECT : Le dernier round de financement ?	AL

Autres langues

26/05	CROSSJECT : The last round of financing?
22/05	Crossject Raises EUR15 Million Via Placing of Shares, Warrants
22/05	CROSSJECT announces the successful completion of an equity financing and warrant issuance for a total immediate gross amount of €15 million
30/04	MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025
30/03	CROSSJECT : Integrating the FY25 numbers
26/03	Crossject Names New Finance Chief
25/03	CROSSJECT appoints Lionel Seltz as Chief Financial Officer
25/03	Crossject Appoints Lionel Seltz as Chief Financial Officer
25/03	CROSSJECT : FY25 results: no big change.
25/03	Crossject Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2025
25/03	CROSSJECT publishes its 2025 financial results and confirms the strengthening of its operational, industrial and financial trajectory
02/02	CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group)
17/11	CROSSJECT : Yet another round of financing
17/11	Crossject Raises EUR5 Million Via Convertible Bonds Issuance
14/11	CROSSJECT completes €5 million financing with Vatel Capital
14/11	Crossject Société Anonyme announced that it has received ?5 million in funding
24/09/25	CROSSJECT presents its financial results and key highlights for the first half of 2025
24/09/25	Crossject Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2025
22/09/25	Crossject Wins Extra $11 Million US Funding to Support Development of Zepizure Drug
22/09/25	CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and FDA Authorization of the ZEPIZURE®? (ZENEO®? Midazolam)
22/09/25	CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and FDA Authorization of the ZEPIZURE® (ZENEO® Midazolam)
19/09/25	Certain Shares of Crossject Société Anonyme are subject to a Lock-Up Agreement Ending on 19-SEP-2025.
25/08/25	CROSSJECT : remains engaged during the summer break
04/08/25	CROSSJECT remains engaged during the summer break
01/07/25	Crossject : Notice to holders of warrants issued in December 2024